IShares Biotechnology is trading at 137.86 as of the 25th of February 2025, a 0.63 percent decrease since the beginning of the trading day. The etf's open price was 138.74. IShares Biotechnology has about a 38 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 28th of October 2024 and ending today, the 25th of February 2025. Click here to learn more.
The fund generally will invest at least 80 percent of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20 percent of its assets in certain futures, options and swap contracts, cash and cash equivalents. More on iShares Biotechnology ETF
Diane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason
Transfer Agent
JPMorgan Chase Bank, N.A.
Fiscal Year End
31-Mar
Exchange
NASDAQ
Number of Constituents
266
Market Maker
Latour Trading
Total Expense
0.45
Management Fee
0.45
Country Name
USA
Returns Y T D
5.07
Name
iShares Biotechnology ETF
Currency Code
USD
Open Figi
BBG000FS8GY0
In Threey Volatility
17.72
1y Volatility
16.18
200 Day M A
140.4
50 Day M A
136.14
Code
IBB
Updated At
25th of February 2025
Currency Name
US Dollar
iShares Biotechnology ETF [IBB] is traded in USA and was established 2001-02-05. The fund is classified under Health category within iShares family. The entity is thematically classified as Health Care ETFs. iShares Biotechnology ETF currently have 7.41 B in assets under management (AUM). , while the total return for the last 3 years was 3.8%.
Check IShares Biotechnology Probability Of Bankruptcy
The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in IShares Biotechnology. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures.
When determining whether iShares Biotechnology ETF offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of IShares Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ishares Biotechnology Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Ishares Biotechnology Etf:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iShares Biotechnology ETF. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
The market value of iShares Biotechnology ETF is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is IShares Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Biotechnology's market value can be influenced by many factors that don't directly affect IShares Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.